The Autonomic Progress Bar Motivates Treatment Completion for Patients of Stimulant Use Disorder and Cannabis Use Disorder

被引:3
|
作者
Chen, I-Chun [1 ,2 ]
Teng, Gloria [3 ]
Chen, Chur-Jen [4 ]
Lan, Tsuo-Hung [1 ,5 ]
Liu, Hung-Jen [2 ,6 ]
机构
[1] Taichung Vet Gen Hosp, Dept Psychiat, Taichung, Taiwan
[2] Natl Chung Hsing Univ, PhD Program Translat Med, Taichung, Taiwan
[3] Xiamen Univ Malaysia, Dept Math, Sepang, Selangor, Malaysia
[4] Tunghai Univ, Dept Appl Math, Taichung, Taiwan
[5] Natl Yang Ming Univ, Fac Med, Taipei, Taiwan
[6] Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan
来源
FRONTIERS IN PSYCHIATRY | 2020年 / 10卷
关键词
mandatory treatment; progress bar; motivation; stimulant use disorder; time series analysis; RANDOMIZED CONTROLLED-TRIAL; SENSITIVITY;
D O I
10.3389/fpsyt.2019.00944
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: The intrinsic motivation behind the "need to complete" is more influential than external incentives. We introduced a novel progress-bar tool to motivate the completion of programs designed to treat stimulant and cannabis use disorders. We further examined the effectiveness of the progress bar's scoring approach in forecasting consistently negative urine tests. Methods: This study's participants included 568 patients with stimulant, amphetamine-type, and cannabis use disorders who were undergoing 12-month mandatory treatment programs at Taichung Veterans General Hospital in Taiwan. Patients were given scores of 1, -1, or 0 depending on whether they received negative, positive, or missing urinalysis reports, respectively. The autonomic progress bar generated weekly score totals. At the group level, score(i) donated scores from all patients for a given week (i denoted the week). Score(i) was standardized to adjusted score(i). We then conducted Autoregressive Integrated Moving Average (ARIMA) Model of time-series analyses for the adjusted score(i). Results: A total of 312 patients maintained treatment progress over the 12-month program. The autonomic score calculator totaled the shared achievements of these patients. The coefficients of the lag variables for mean (p), lag variables for residual error term (q), and number of orders for ensuring stationary (d) were estimated at p = 3, d = 4, and q = 7 for the first half of the treatment program, and were estimated at p = 2, d = 2, and q = 3 for the second half. Both models were stationary and tested as fit for prediction (p < 0.05). Sharply raised adjusted scores were predicted during the high-demand treatment phase. Discussion: This study's novel progress-bar tool effectively motivated treatment completion. It was also effective in forecasting continually negative urine tests. The tool's free open-source code makes it easy to implement among many substance-treatment services.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Cannabis use and cannabis use disorder
    Jason P. Connor
    Daniel Stjepanović
    Bernard Le Foll
    Eva Hoch
    Alan J. Budney
    Wayne D. Hall
    Nature Reviews Disease Primers, 7
  • [2] Cannabis use and cannabis use disorder
    Connor, Jason P.
    Stjepanovic, Daniel
    Le Foll, Bernard
    Hoch, Eva
    Budney, Alan J.
    Hall, Wayne D.
    NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
  • [4] Quetiapine treatment for cannabis use disorder
    Mariani, John J.
    Pavlicova, Martina
    Choi, C. Jean
    Basaraba, Cale
    Carpenter, Kenneth M.
    Mahony, Amy L.
    Brooks, Daniel J.
    Bisaga, Adam
    Naqvi, Nasir
    Nunes, Edward, V
    Levin, Frances R.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 218
  • [5] Pharmacotherapy for the Treatment of Cannabis Use Disorder
    Brezing, Christina A.
    Levin, Frances R.
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (03) : 247 - 248
  • [6] Developments in the treatment of cannabis use disorder
    Copeland, J
    CURRENT OPINION IN PSYCHIATRY, 2004, 17 (03) : 161 - 167
  • [7] Transcranial Stimulation for the Treatment of Stimulant Use Disorder
    Edinoff, Amber N.
    Sall, Saveen
    Roberts, T. Dean
    Tomlinson, Henry H.
    Soileau III, Lenise G. G.
    Jackson, Eric D.
    Murnane, Kevin S.
    Wenger, Danielle M.
    Cornett, Elyse M.
    Toms, Jaime
    Kumbhare, Deepak
    Kaye, Adam M.
    Kaye, Alan D.
    NEUROLOGY INTERNATIONAL, 2023, 15 (01): : 325 - 338
  • [8] Shared genetics of ADHD, cannabis use disorder and cannabis use and prediction of cannabis use disorder in ADHD
    Nielsen, Trine Tollerup
    Duan, Jinjie
    Levey, Daniel F.
    Walters, G. Bragi
    Johnson, Emma C.
    Thorgeirsson, Thorgeir
    VA Million Veteran Program, Daniel F.
    Werge, Thomas
    Mortensen, Preben Bo
    Stefansson, Hreinn
    Stefansson, Kari
    Hougaard, David M.
    Agrawal, Arpana
    Gelernter, Joel
    Grove, Jakob
    Borglum, Anders D.
    Demontis, Ditte
    NATURE MENTAL HEALTH, 2024, 2 (09): : 1071 - 1083
  • [9] Contingency Management for Stimulant Use Disorder Progress, Challenges, and Recommendations
    Rawson, Richard A.
    Erath, Tyler G.
    Chalk, Mady
    Clark, H. Westley
    McDaid, Carol
    Wattenberg, Sarah A.
    Roll, John M.
    McDonell, Michael G.
    Parent, Sara
    Freese, Thomas E.
    JOURNAL OF AMBULATORY CARE MANAGEMENT, 2023, 46 (02): : 152 - 159
  • [10] Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration
    Frost, Madeline C.
    Coughlin, Lara N.
    Zhang, Lan
    Lin, Lewei
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (05) : 561 - 566